Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acamprosate for Alcohol Withdrawal
NCT00106106Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Mar 2005
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol withdrawal syndrome (AWS) comparing Acamprosate with Placebo (2 arms). Primary endpoint: Ratio of Glutamate to Creatine in the Anterior Cingulate at Day 25. Started Mar 2005; status: completed.
02
Drugs
acamprosate
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on NCT00106106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00106106.